ARBUTUS BIOPHARMA CORP (ABUS)
CA03879J1003 - Common Stock
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging...
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
The healthcare industry is one of the most potent yet also one of the most competitive. This has short sellers out for blood.
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging...
Noteworthy Wednesday Option Activity: DDOG, ABUS, JNJ
Commit To Buy Arbutus Biopharma At $2, Earn 19.3% Annualized Using Options
Arbutus to Participate in Two Upcoming Investor Conferences
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging...
Notable Wednesday Option Activity: MRNS, ABUS, ASO
Arbutus Biopharma GAAP EPS of -$0.44 beats by $0.01, revenue of $18.1M misses by $3.04M (NASDAQ:ABUS)
Arbutus Biopharma reports lower revenue in 2023, primarily due to a decrease in license agreement recognition and sales decline.
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 ...
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging...
Arbutus Biopharma stock gains after Markman hearing on Thursday in Moderna dispute
Arbutus Biopharma's stock jumped 8% following positive developments in its vaccine patent dispute with Moderna, a biotechnology company.
Notable Friday Option Activity: ABUS, HD, CAR
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other...
Commit To Buy Arbutus Biopharma At $2, Earn 50.2% Annualized Using Options
Noteworthy Tuesday Option Activity: LZB, VSTO, ABUS
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in...
Arbutus to Present at Jefferies London Healthcare Conference
Arbutus to Present at Jefferies London Healthcare Conference
WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage...
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage...
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
WARMINSTER, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage...
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
Imdusiran data will be highlighted in late breaking presentation WARMINSTER, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
Arbutus stock lower after FDA snub for Alnylam drug
The FDA rejection of Alnylam's amyloidosis therapy impacts Arbutus Biopharma, which has a licensing deal with the company for the product. Read more here.